

[0029] In one aspect, provided herein are immunoconjugates comprising an anti-CD79b antibody of described herein and a cytotoxic agent.

[0030] In one aspect, provided herein are pharmaceutical compositions comprising the anti-CD79b antibody described herein.

[0031] In one aspect, provided herein are anti-CD79b antibodies as described herein for use as a medicament. In another aspect, provided herein are anti-CD79b antibody described herein for use in treating or delaying progression of a B cell proliferative disorder or an autoimmune disorder in a subject in need thereof. In yet another aspect, provided herein are anti-CD79b antibodies as described herein for use in enhancing immune function in a subject having a B cell proliferative disorder or an autoimmune disorder. In some embodiments, the B cell proliferative disorder is a cancer. In some embodiments, the B cell proliferative disorder is lymphoma, non-Hodgkins lymphoma (NHL), aggressive NHL, relapsed aggressive NHL, relapsed indolent NHL, refractory NHL, refractory indolent NHL, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, leukemia, hairy cell leukemia (HCL), acute lymphocytic leukemia (ALL), and/or mantle cell lymphoma. In some embodiments of any of the B cell proliferative disorders, the B cell proliferative disorder is resistant to treatment with an anti-CD79b antibody drug conjugate (e.g., anti-CD79b MMAE antibody drug conjugate). In some embodiments, the autoimmune disorder is selected from the group consisting of rheumatoid arthritis, juvenile rheumatoid arthritis, systemic lupus erythematosus (SLE), Wegener's disease, inflammatory bowel disease, idiopathic thrombocytopenic purpura (ITP), thrombotic thrombocytopenic purpura (TTP), autoimmune thrombocytopenia, multiple sclerosis, psoriasis, IgA nephropathy, IgM polyneuropathies, myasthenia gravis, vasculitis, diabetes mellitus, Reynaud's syndrome, Sjorgen's syndrome, glomerulonephritis, Neuromyelitis Optica (NMO) and IgG neuropathy.

[0032] In one aspect, provided herein are uses of any of the anti-CD79b antibody described herein in the manufacture of a medicament for treating or delaying progression of a B cell proliferative disorder. Also provided herein are uses of any of the anti-CD79b antibody described herein in the manufacture of a medicament for enhancing immune function in a subject having a cell proliferative disorder or an autoimmune disorder. In some embodiments, the B cell proliferative disorder is a cancer. In some embodiments, the B cell proliferative disorder is lymphoma, non-Hodgkins lymphoma (NHL), aggressive NHL, relapsed aggressive NHL, relapsed indolent NHL, refractory NHL, refractory indolent NHL, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, leukemia, hairy cell leukemia (HCL), acute lymphocytic leukemia (ALL), and/or mantle cell lymphoma. In some embodiments of any of the B cell proliferative disorders, the B cell proliferative disorder is resistant to treatment with an anti-CD79b antibody drug conjugate (e.g., anti-CD79b MMAE antibody drug conjugate). In some embodiments, the autoimmune disorder is selected from the group consisting of rheumatoid arthritis, juvenile rheumatoid arthritis, systemic lupus

23. The anti-CD79b antibody of claim 21, wherein the antibody comprises an N297G substitution mutation at amino acid residue 297 according to EU numbering.

24. The anti-CD79b antibody of any one of claims 1-23, wherein the anti-CD79b antibody is a monospecific antibody (e.g., bivalent, dual arm antibody).

25. The anti-CD79b antibody of any one of claims 1-23, wherein the anti-CD79b antibody is a multispecific antibody.

26. The anti-CD79b antibody of claim 25, wherein the multispecific antibody comprises a CD3 binding domain.

27. The anti-CD79b antibody of claim 26, wherein the CD3 binding domain binds to a human CD3 polypeptide or a cynomolgus monkey (cyno) CD3 polypeptide.

28. The anti-CD79b antibody of claim 27, wherein the human CD3 polypeptide or the cyno CD3 polypeptide is a human CD3 ϵ polypeptide or a cyno CD3 ϵ polypeptide, respectively.

29. The anti-CD79b antibody of claim 27, wherein the human CD3 polypeptide or the cyno CD3 polypeptide is a human CD3 γ polypeptide or a cyno CD3 γ polypeptide, respectively.

30. The anti-CD79b antibody of any one of claims 26-29, wherein the CD3 binding domain comprises the following six HVRs:

- (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:45;
- (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:46;
- (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:47;
- (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:48;
- (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:49; and
- (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:50.

31. The anti-CD79b antibody of any one of claims 26-30, wherein the CD3 binding domain comprises a VH sequence of SEQ ID NO:59.

32. The anti-CD79b antibody of any one of claims 26-31, wherein the CD3 binding domain comprises a VL sequence of SEQ ID NO:60.

33. The anti-CD79b antibody of any one of claims 26-29, wherein the CD3 binding domain comprises the following six HVRs:

- (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:39;
- (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:40;

- (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:41;
- (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:42;
- (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:43; and
- (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:44.

34. The anti-CD79b antibody of any one of claims 26-29 or 33, wherein the CD3 binding domain comprises a VH sequence of SEQ ID NO:57.

35. The anti-CD79b antibody of any one of claims 26-29 or 33-34, wherein the CD3 binding domain comprises a VL sequence of SEQ ID NO:58.

36. The anti-CD79b antibody of any one of claims 26-29, wherein the CD3 binding domain comprises the following six HVRs:

- (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:51;
- (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:52;
- (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:53;
- (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:54;
- (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:55; and
- (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:56.

37. The anti-CD79b antibody of any one of claims 26-29 or 36, wherein the CD3 binding domain comprises a VH sequence of SEQ ID NO:61.

38. The anti-CD79b antibody of any one of claims 26-29 or 36-37, wherein the CD3 binding domain comprises a VL sequence of SEQ ID NO:62.

39. The anti-CD79b antibody of any one of claims 25-38, wherein the multispecific antibody is a bispecific antibody.

40. The anti-CD79b antibody of any one of claims 25-39, wherein the anti-CD79b antibody has a B cell killing EC₅₀ of less than about 100 ng/mL.

41. The anti-CD79b antibody of claim 40, wherein the B cell killing is endogenous B cell killing or cell line B cell killing, e.g., BJAB cell line, WSU-CLCL2 cell line, OCI-Ly-19 cell line.

42. The anti-CD79b antibody of any one of claims 25-41, wherein the anti-CD79b antibody has a cytotoxic T cell activation EC_{50} of less than about 50 ng/mL.

43. The anti-CD79b antibody of any one of claims 26-42, wherein (a) the CD3 binding domain comprises a Fc domain, wherein the Fc domain comprises T366S, L368A, Y407V, and N297G substitution mutations according EU numbering and (b) the CD79b binding domain comprises a Fc domain, wherein the Fc domain comprises T366W and N297G substitution mutations according EU numbering.

44. An isolated nucleic acid encoding the anti-CD79b antibody of any one of claims 1-43.

45. A vector comprising the isolated nucleic acid of claim 44.

46. A host cell comprising the vector of claim 45.

47. A method of producing the anti-CD79b antibody of any one of claims 1-43, the method comprising culturing the host cell of claim 46 in a culture medium.

48. An immunoconjugate comprising the anti-CD79b antibody of any one of claims 1-43 and a cytotoxic agent.

49. A pharmaceutical composition comprising the anti-CD79b antibody of any one of claims 1-43.

50. The anti-CD79b antibody of any one of claims 1-43 for use as a medicament.

51. The anti-CD79b antibody of any one of claims 1-43 for use in treating or delaying progression of a B cell proliferative disorder or an autoimmune disorder in a subject in need thereof.

52. The anti-CD79b antibody of any one of claims 1-43 for use in enhancing immune function in a subject having a B cell proliferative disorder or an autoimmune disorder.

53. The anti-CD79b antibody of any one of claims 51-52, wherein the B cell proliferative disorder is a cancer.

54. The anti-CD79b antibody of any one of claims 51-53, wherein the B cell proliferative disorder is lymphoma, non-Hodgkins lymphoma (NHL), aggressive NHL, relapsed aggressive NHL, relapsed indolent NHL, refractory NHL, refractory indolent NHL, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, leukemia, hairy cell leukemia (HCL), acute lymphocytic leukemia (ALL), and/or mantle cell lymphoma.

55. Use of the anti-CD79b antibody of any one of claims 1-43 in the manufacture of a medicament for treating or delaying progression of a B cell proliferative disorder.

56. The use of claim 55, wherein the B cell proliferative disorder is a cancer.
57. The use of any one of claims 55-56 wherein the B cell proliferative disorder is lymphoma, NHL, aggressive NHL, relapsed aggressive NHL, relapsed indolent NHL, refractory NHL, refractory indolent NHL, CLL, small lymphocytic lymphoma, leukemia, HCL, ALL, and/or mantle cell lymphoma.
58. The use of any one of claims 55-57, wherein the medicament is to be administered with a PD-1 axis binding antagonist or an additional therapeutic agent.
59. The use of any one of claims 55-58, wherein the medicament is to be administered with a glucocorticoid.
60. The use of claim 59, wherein the glucocorticoid is dexamethasone.
61. The use of any one of claims 55-61, wherein the medicament is to be administered with rituximab.